Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Non-Hodgkin Lymphoma: More Common But More Curable

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Blood / Hematology;  Cancer / Oncology
Article Date: 02 Sep 2009 - 14:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions
Current Article Ratings:

Patient / Public:3 and a half stars

3.5 (4 votes)

Health Professional:not yet rated

Article Opinions: 1 posts

Cases of non-Hodgkin lymphoma have more than tripled in the last thirty years according to the latest Cancer Research UK figures published today.

Overall the number of people diagnosed with the disease in Great Britain has risen from over 3,000 in 1975 to more than 10,300 in 2006.

Similar to the rise in cases, the overall rate of people dying from the disease rose until 1999; but it has been falling since 2002 from 6 per 100,000, down to 5.2 per 100,000 in 2007 in the UK.

Experts believe the rise in cases over the past 30 years can be attributed to an ageing population and to an increase in the number of older people developing large B-cell lymphoma - an aggressive form of the disease, but one which can now often be successfully treated.

The fall in death rates can be traced to clinical trials which have led to the introduction of new treatments such as the antibody rituximab, approved for use in UK patients in 2000.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "These figures reflect the progress made in the treatment and care of patients with non- Hodgkin lymphoma.

"An ageing population and a rise in the number of older people developing more aggressive forms of lymphoma are the main reasons behind the increase we have seen in the number of cases over the last few decades.

"But thanks to a huge investment in lymphoma clinical trials which have helped develop new treatments - most notably rituximab - the rate of death from the disease is dropping.

"Cancer Research UK continues to fund a number of lymphoma trials and we hope to see yet more improvements in survival in the future."

Notes

There were 3,294 cases of non-Hodgkin lymphoma (NHL) in 1975 compared with 10,312 in 2006 in Great Britain. The corresponding age-standardised incidence rates were 5.5 per 100, 000 population in 1975 and 13.9 per 100,000 in 2006.

There were 1,880 deaths from NHL in 1971; 4,754 deaths from NHL in 2002 and 4,533 in 2007 in the UK. The corresponding age-standardised mortality rates were 3.1 in 1971; 6.0 in 2002 and 5.2 per 100,000 population in 2007.

For more information about non-Hodgkin lymphoma go to http://www.cancerhelp.org.uk

Source
Cancer Research UK


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Haiti Appeal

Haiti Appeal Image
The severe earthquake that struck Haiti has inflicted damage and devastation on a massive scale. Please donate to the Doctors Without Borders Haiti Appeal.

PLEASE DONATE HERE


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Multiple Myeloma? What Causes Multiple Myeloma?
25 Aug 2009
Multiple myeloma, also known as myeloma or plasma cell myeloma, is cancer of the plasma cells - a kind of white blood cell which is present in the bone marrow. Plasma cells make antibodies called immunoglobulin which help fight off infections...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...